![Philip J. Coggins](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Philip J. Coggins
Former positions of Philip J. Coggins
Companies | Position | Start | End |
---|---|---|---|
Osprey Pharmaceuticals Ltd.
![]() Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | Chief Tech/Sci/R&D Officer | 2010-02-09 | 2012-06-28 |
Founder | 2010-02-09 | 2012-06-28 | |
President | 1996-12-31 | 2012-06-28 | |
McMaster University | Corporate Officer/Principal | - | - |
Training of Philip J. Coggins
The University of Manchester | Undergraduate Degree |
Newcastle University | Doctorate Degree |
Statistics
International
Canada | 3 |
Israel | 2 |
United Kingdom | 2 |
Operational
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
President | 1 |
Sectoral
Consumer Services | 4 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Osprey Pharmaceuticals Ltd.
![]() Osprey Pharmaceuticals Ltd. Pharmaceuticals: GenericHealth Technology Osprey Pharmaceuticals Ltd. develops a series of proprietary therapeutic drugs. Osprey Pharmaceuticals is developing a unique family of therapeutic proteins capable of treating chronic diseases. Osprey's broad technology platform is based on the critical insight that many common diseases are propagated by overabundant and overactive leukocytes. The Company's patented Leukocyte Population Modulators (LPMs) selectively and systematically remove these disease-related leukocytes by targeting the chemokine system a complex network of small proteins and their receptors that regulate the movement and activity of leukocytes. The Company's lead compound is in early clinical development for the treatment of diseases associated with chronic inflammation. Osprey also has a portfolio of preclinical LPMs that target a variety of diseases including inflammatory and immunological disorders, oncology, and cardiovascular disease. Osprey Pharmaceuticals was founded in 1997 and is located in Saint-Laurent, Canada. | Health Technology |
- Stock Market
- Insiders
- Philip J. Coggins
- Experience